Business, energy, technology, markets and global industry news from Business News Today

GSPT1

PharmaDeviceNews GSPT1
Orum’s ORM-1153 is moving toward an approximately 42-patient Phase 1 study after FDA clearance, testing whether a CD123-targeting conjugate can selectively deliver a GSPT1 protein degrader into acute myeloid leukemia cells and translate targeted protein degradation into a new precision-oncology strategy. Representative image.
Pharma & Biotech

Orum takes ORM-1153 into human testing after FDA clears first-in-human AML study

Orum plans an approximately 42-patient Phase 1 study of ORM-1153 after FDA cleared the CD123-targeting conjugate to deliver a GSPT1 protein degrader into AML cells.

Read More
Representative image of acute myeloid leukemia research, illustrating how Orum Therapeutics’ ORM-1153 AACR 2026 data are drawing attention to CD123-targeting degrader-antibody conjugates in AML.
Pharma & Biotech

Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention

Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.

Read More
Pharma & Biotech

How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML

Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.

Read More